Paeds Vivas · clinical-pharmacology-and-therapeutics
Endocrine and diabetes medicines — branching viva
Branching viva on diabetic ketoacidosis insulin and fluid prescribing, a neonatal levothyroxine start, growth hormone dose and safety surveillance, and an adolescent insulin regimen at transition.
On this page
Study tools
Target exams
RACP General PaediatricsRACP DCEMRCPCH ClinicalRCPSC Pediatrics
Prompt
You are the paediatric registrar. The examiner moves you through four linked endocrine prescribing problems: a child in DKA, a neonate with a positive thyroid screen, a child starting growth hormone, and an adolescent with erratic control nearing transition to adult care.
Station map
Branch A — Diabetic ketoacidosis: insulin and fluids
Examiner: A 7-year-old presents drowsy with Kussmaul breathing, bedside glucose 24 mmol per L, ketones 6.2 mmol per L and venous pH 7.08. She is 7 percent dehydrated but not in shock. Talk me through your insulin and fluid prescribing. [4]
Strong answer should include:
- Restore intravascular volume first with isotonic saline; a 10 to 20 mL per kg bolus only if shocked, otherwise calculated deficit replacement over 24 to 48 hours. [4]
- Start the continuous intravenous insulin infusion at 0.05 to 0.1 unit per kg per hour only after volume is restored. [4]
- Never give an intravenous insulin bolus in paediatric DKA, because the steep osmolar fall contributes to cerebral oedema. [4] [9]
- Replace potassium once insulin starts and urine output is established; add dextrose when glucose falls to around 11 to 14 mmol per L. [4]
- Transition to subcutaneous insulin only when ketones clear, the pH normalises, and the child is eating.
Examiner probe: Why is insulin, not fluids or bicarbonate, the definitive treatment? [4]
Strong answer should include:
- DKA is an insulin-deficient ketotic state; insulin restores glucose uptake and switches off lipolysis and ketogenesis. [4]
- Fluids restore volume but do not stop ketogenesis; bicarbonate is avoided because it does not improve outcome and may worsen cerebral acidosis. [9]
Branch B — Neonatal levothyroxine
References7ShowHide
- [1]Cengiz E, Danne T, et al International Society for Pediatric and Adolescent Diabetes Clinical Practice Consensus Guidelines 2024: Insulin and Adjunctive Treatments in Children and Adolescents with Diabetes Horm Res Paediatr, 2024.PMID 39884261
- [2]de Bock M, Agwu JC, et al International Society for Pediatric and Adolescent Diabetes Clinical Practice Consensus Guidelines 2024: Glycemic Targets Horm Res Paediatr, 2024.PMID 39701064
- [4]Wolfsdorf JI, Glaser N, et al ISPAD Clinical Practice Consensus Guidelines 2018: Diabetic ketoacidosis and the hyperglycemic hyperosmolar state Pediatr Diabetes, 2018.PMID 29900641
- [6]Léger J, Olivieri A, et al European Society for Paediatric Endocrinology consensus guidelines on screening, diagnosis, and management of congenital hypothyroidism J Clin Endocrinol Metab, 2014.PMID 24446653
- [9]Azova S, Rapaport R, et al Brain injury in children with diabetic ketoacidosis: Review of the literature and a proposed pathophysiologic pathway for the development of cerebral edema Pediatr Diabetes, 2021.PMID 33197066
- [7]Esposito A, Vigone MC, et al Effect of initial levothyroxine dose on neurodevelopmental and growth outcomes in children with congenital hypothyroidism Front Endocrinol (Lausanne), 2022.PMID 36133316
- [12]Chen SC, Bryce J, et al Development of a Minimum Dataset for the Monitoring of Recombinant Human Growth Hormone Therapy in Children with Growth Hormone Deficiency: A GloBE-Reg Initiative Horm Res Paediatr, 2024.PMID 37703843